172 related articles for article (PubMed ID: 17919639)
1. [Hemoglobin target for chronic kidney disease patients?].
Drüeke TB
Nephrol Ther; 2007 Oct; 3(6):369-71. PubMed ID: 17919639
[No Abstract] [Full Text] [Related]
2. Hemoglobin normalization trials in chronic kidney disease: what should we learn about quality of life as an end point?
Covic A; Seica A; Gusbeth-Tatomir P; Goldsmith D
J Nephrol; 2008; 21(4):478-84. PubMed ID: 18651536
[TBL] [Abstract][Full Text] [Related]
3. [Therapeutic target for the use of erythropoietin (EPO): is subnormal better than normal?].
Karle H; Hansen NE
Ugeskr Laeger; 2007 May; 169(19):1782-3. PubMed ID: 17537352
[No Abstract] [Full Text] [Related]
4. Treatment of anaemia in chronic renal failure.
Beer J
Nurs Times; 1988 Nov 23-29; 84(47):55-7. PubMed ID: 3211795
[No Abstract] [Full Text] [Related]
5. The target hemoglobin in patients with chronic kidney disease.
Singh AK
Nephrol News Issues; 2006 Dec; 20(13):29-30. PubMed ID: 17168056
[No Abstract] [Full Text] [Related]
6. [Variability of the hemoglobin level: each patient is unique].
Zaoui P; Deray G; Ortiz JP; Rostaing L
Nephrol Ther; 2011 Feb; 7(1 Suppl 2):H1-4. PubMed ID: 21371677
[No Abstract] [Full Text] [Related]
7. Hemoglobin variability in dialysis patients.
Brimble KS; Clase CM
J Am Soc Nephrol; 2007 Aug; 18(8):2218-20. PubMed ID: 17627931
[No Abstract] [Full Text] [Related]
8. Clinical experience with darbepoetin-alfa (Aranesp).
Locatelli F; Del Vecchio L; Marai P
Contrib Nephrol; 2002; (137):403-7. PubMed ID: 12101985
[No Abstract] [Full Text] [Related]
9. Hemoglobin normalization studies.
Reddan D; Lappin DW; Tierney M; Szczech LA
Perit Dial Int; 2007; 27(4):395-9. PubMed ID: 17602145
[No Abstract] [Full Text] [Related]
10. Hemoglobin levels, quality of life, and survival.
Sadler JH; Meyer KB
Nephrol News Issues; 2007 Aug; 21(9):42-3. PubMed ID: 17722853
[No Abstract] [Full Text] [Related]
11. [How to optimize the concept of the variability of haemoglobin in dialysis patients].
Kessler M
Nephrol Ther; 2008 Dec; 4(7):547-8. PubMed ID: 18809370
[No Abstract] [Full Text] [Related]
12. Erythropoietin resistance during androgen deficiency.
Daniell HW
Arch Intern Med; 2006 Sep; 166(17):1923; author reply 1923-4. PubMed ID: 17000951
[No Abstract] [Full Text] [Related]
13. Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con.
Himmelfarb J; Szczech LA
J Am Soc Nephrol; 2009 Jul; 20(7):1441-3. PubMed ID: 19579287
[No Abstract] [Full Text] [Related]
14. [Treatment of anemia caused by chronic kidney failure in adults].
Nephrol Ther; 2005 Aug; 1 Suppl 1():S1-48. PubMed ID: 16895707
[No Abstract] [Full Text] [Related]
15. [Erythropoietin in 1991--pathophysiological and therapeutic aspects].
Wiecek A
Przegl Lek; 1992; 49(1-2):31-5. PubMed ID: 1455002
[No Abstract] [Full Text] [Related]
16. [Erythropoietin in the treatment of anemia in chronic renal insufficiency].
Valderrábano F
An Med Interna; 1991 Jun; 8 Suppl 2():22-3. PubMed ID: 1878467
[No Abstract] [Full Text] [Related]
17. New developments in anemia management in chronic kidney disease.
Amerling R; Besarab A; Roy C
Nephrol News Issues; 2008 Mar; 22(3):suppl 1-8. PubMed ID: 18372676
[No Abstract] [Full Text] [Related]
18. We are overreacting to our hemoglobin fear.
Sadler JH
Nephrol News Issues; 2007 Jun; 21(7):48. PubMed ID: 17623985
[No Abstract] [Full Text] [Related]
19. Erythropoietin for the anemia of chronic renal failure.
Schwartz AB; Prior J; Terzian L; Kahn B
Am Fam Physician; 1988 Jun; 37(6):211-5. PubMed ID: 3289343
[No Abstract] [Full Text] [Related]
20. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
